Skip to main content

BioCommunique Article

Bringing you the latest financial and strategic news from top leaders in life science over the past two weeks.

Pfizer touts late-stage win for JAK drug, Vertex follows pharma lead in bet on protein degradation, Grail nets FDA breakthrough status for early cancer detection

  • 2019-05-16T23:51:00.000+0000
  • California
  • Author: Lauren Panetta

5/16/19 – GEN
Genentech, Parvus Therapeutics launch up-to-$800M autoimmune collaboration

5/16/19 – FierceBiotech
Amgen posts early clinical data on closely watched KRAS drug

5/15/19 – BioPharma Dive
Pfizer touts late-stage win for JAK drug that could duel with Dupixent

5/15/19 – FierceBiotech
Thermo Fisher blood test study tracks tumor evolutions over time

5/15/18 – BioPharma Dive
Vertex follows pharma lead in bet on protein degradation

5/14/19 – FierceBiotech
Myovant hits goal in uterine fibroid phase 3

5/14/19 – The San Diego Union Tribune
Experimental liver cancer drug developed at Scripps Research cleared for testing

5/14/19 – FierceBiotech
Grail nets FDA breakthrough status for early cancer detection

5/13/19 – BioPharma Dive
Bayer pumping $150M more into biologics

5/10/19 – The San Diego Union-Tribune
San Diego’s AmpliPhi merges with Marina del Rey biotech

5/10/19 – The San Diego Union-Tribune
BioLegend opens new San Diego headquarters

5/9/19 – San Diego Business Journal
UC San Diego researchers get $4.7M for Crohn’s Disease efforts

5/9/19 – GEN
Takeda sells two drugs for $5.7B+, licenses a third, in deals aimed at refocusing pipeline

5/9/19 – Endpoints
Bayer kicks off a $150M add-on for its campus in Berkeley

5/8/19 – FierceBiotech
Pear, Novartis begin testing an app for MS-related depression

5/8/19 – BioPharma Dive
Pfizer to buy Therachon for $340M, taking on BioMarin, Ascendis

5/8/19 – The San Diego Union-Tribune
San Diego startup LunaDNA pulls in $4.6 million to boost health data research platform

5/6/19 – FierceBiotech
Takeda taps Skyhawk's RNA tech for neurodegenerative disease

5/6/19 – The San Diego Union-Tribune
San Diego’s Abide Therapeutics sold for $250 million to Danish drug company

5/6/19 – BioPharma Dive
'Pathbreaking' Ionis trial offers way forward in Huntington's disease